血清HBV RNA在临床应用中尚未解决的关键科学问题

摘要/Abstract

摘要： 乙型肝炎病毒(hepatitis B virus,HBV)感染导致的慢性乙型肝炎(chronic hepatitis B,CHB)难以完全治愈,其根本原因是肝内共价闭合环状DNA(covalently closed circular DNA,cccDNA)持续稳定存在。血清HBV RNA作为cccDNA的下游转录产物,近年越来越多研究表明可用于监测CHB患者的疾病进展和预测预后。为了更好地了解血清HBV RNA,本文梳理了当前尚未解决的三个关键科学问题,包括血清HBV RNA的检测方法学、血清HBV RNA反映cccDNA状态的能力以及HBV RNA与肝细胞癌(hepatocellular carcinoma,HCC)发生、发展的关系,旨在进一步挖掘血清HBV RNA的临床价值。

关键词: 乙型肝炎病毒, 慢性乙型肝炎, 脱氧核糖核酸, 临床应用

黎婉莹, 申笙, 刘诗, 孙剑. 血清HBV RNA在临床应用中尚未解决的关键科学问题[J]. 肝脏, 2024, 29(2): 143-146.

参考文献

[1] Who. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021[J]. https://www.who.int/publications/i/item/9789240027077, 2021.
[2] Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403.
[3] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238.
[4] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
[5] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331.
[6] 刘燕娜,樊蓉,杨瑞锋,等. 慢性HBV感染者血清HBV RNA检测及临床应用的专家共识[J]. 中华肝脏病杂志, 2022, 30(5): 505-512.
[7] Deng R, Liu S, Shen S, et al. Circulating HBV RNA: From biology to clinical applications[J]. Hepatology, 2022, 76(5): 1520-1530.
[8] Zaiets I, Gunewardena S, Menne S, et al. Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication or Derived from Integrated HBV DNA[J]. J Virol, 2023, 97(3):e0195022.
[9] Fan R, Zhou B, Xu M, et al. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 719-727.
[10] Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J]. Hepatology, 2007, 45(5): 1179-1186.
[11] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710.
[12] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015, 61(1): 66-76.
[13] Liu S, Wu Y, Deng R, et al. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients[J]. Antiviral Res, 2021, 189: 105037.
[14] Liu S, Zhou B, Valdes JD, et al. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection[J]. Hepatology, 2019, 69(4): 1816-1827.
[15] Huang Q, Zhou B, Cai D, et al. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients[J]. Hepatology (Baltimore, Md.), 2021, 73(1): 41-52.
[16] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-na?ve HBV-infected individuals[J]. J Clin Virol, 2018, 99-100: 71-78.
[17] Gao Y, Li Y, Meng Q, et al. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?[J]. J Clin Microbiol, 2017, 55(10): 2972-2982.
[18] Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment[J]. Virol J, 2021, 18(1):4.
[19] Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection[J]. J Viral Hepat, 2018, 25(9): 1038-1047.
[20] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2018, 68(1): 16-24.
[21] Wang Y, Niklasch M, Liu T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72(5): 865-876.
[22] Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176): 1221-1228.
[23] Belloni L, Allweiss L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122(2): 529-537.
[24] Liu S, Deng R, Zhou B, et al. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy[J]. J Infect Dis, 2022, 226(5): 881-890.
[25] Ding WB, Wang MC, Yu J, et al. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3[J]. Hepatology, 2021, 74(3): 1480-1495.
[26] Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(7): 765-769.
[27] Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma[J]. Gut, 2022, 71(3): 616-626.
[28] Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64(1, Supplement): S84-S101.
[29] Chen W, Chen J, Jiao B, et al. Interaction of the Hepatitis B Spliced Protein with Cathepsin B Promotes Hepatoma Cell Migration and Invasion[J]. J Virol, 2012, 86(24): 13533-13541.
[30] Xu X, Zhang L, Ye G, et al. Hepatitis B doubly spliced protein (HBDSP) promotes hepatocellular carcinoma cell apoptosis via ETS1/GATA2/YY1-mediated p53 transcription[J]. J Virol, 2023,97(11):e0108723.
[31] Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204.
[32] Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B[J]. Eur J Intern Med, 2021, 84: 68-73.
[33] 刘慧,鲁凤民,郭巨涛. 乙型肝炎病毒核心蛋白变构调节剂的作用机理及临床研发和应用前景[J]. 临床肝胆病杂志, 2022, 38(8): 1726-1732.